<DOC>
	<DOCNO>NCT01856088</DOCNO>
	<brief_summary>The main objective study evaluate effectiveness stent Inspiron ™ sirolimus-eluting coat abluminal biodegradable stent Biomatrix Flex ™ lesion native coronary artery .</brief_summary>
	<brief_title>DESTINY TRIAL ( Inspiron x Biomatrix )</brief_title>
	<detailed_description>This study non-inferiority , multicentre , prospective , randomized two treatment arm : I ) Inspiron ™ stent elute sirolimus II ) ™ Biomatrix stent elute biolimus . Are total 165 randomized patient . Patients follow 60 month procedure . All new patient undergoing angiography evaluation 9 month . A subgroup 60 patient evaluate volumetric intravascular ultrasound 9 month . Also , subgroup 21 patient evaluated optical coherence tomography end index procedure 9 month . It anticipate total study duration 72 month : 12 month complete admission patient 60 month follow-up .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Age &gt; 18 year ; 2 . Symptomatic ischemic heart disease / objective evidence myocardial ischemia one two target lesion locate different epicardial vessel ; 3 . A ( ) lesion ( ) target ( ) must : 1 . Again ( restenotic ) ; 2 . Located native coronary artery diameter 2.5 3.5 mm ( visual ) ; 3 . Can treat single stent 29 mm length ; 4 . Obstruction stenosis &gt; 50 % diameter ( visual ) ; 4 . Acceptable candidate CABG ; 5 . The patient inform nature study , agree rule provide write informed consent approve local Ethics Committee . 1 . Women childbearing age history surgical sterilization ; 2 . Myocardial infarction Q wave occur last 48 hour index procedure ; 3 . Myocardial infarction without Q wave cardiac marker even high level ; 4 . Ejection fraction &lt; 30 % ; 5 . Impaired renal function ( creatinine &gt; 2.0 mg / dl ) calculate creatinine clearance &lt; 60 ml / min ; 6 . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 ; 7 . Total leukocyte count &lt; 3000 cells/mm3 ; 8 . Documented suspect liver disease ( include laboratory evidence hepatitis ) ; 9 . Heart transplant recipient ; 10 . Known allergy aspirin , clopidogrel , ticlopidine , paclitaxel , sirolimus , heparin stainless steel ; 11 . Patient life expectancy le 12 month ; 12 . Any significant medical condition opinion investigator would interfere ideal patient participation study ; 13 . Participation research last 12 month , unless direct benefit research subject ; 14 . Coronary angioplasty ( without stenting ) less 6 month anywhere target vessel ; 15 . Coronary angioplasty ( without stenting ) prior time segment Diste le 5 mm ( proximal distal ) lesion ; 16 . Coronary angioplasty ( without stenting ) schedule first 12 month index procedure segment target vessel . EXCLUSION CRITERIA angiographic 1 . Restenotic target lesion ; 2 . Need treatment one lesion vessel ; 3 . Need treatment three lesion procedure ; 4 . Target vessel diameter &lt; 2.5 mm &gt; 3.5 mm ( visual ) ; 5 . Target lesion long susceptible treatment single stent 29mm length , accord judgment operator ; 6 . Lesion coronary artery unprotected ( &gt; 50 % stenosis ) ; 7 . Angiographic thrombus ; 8 . Target lesion surgical graft ; 9 . Total occlusion ( TIMI anterograde flow 0 1 ) ; 10 . Ostial lesion ; 11 . The target lesion bifurcation side branch may require intervention procedure , without stenting ; 12 . Injuries impossible anticipate predilatation successfully necessary use rotablator ; 13 . The target vessel excessive tortuosity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Coronary artery</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>thrombosis</keyword>
</DOC>